The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)

被引：50

作者：

Basile, Jan N. ^{[1
]}

机构：

[1] Med Univ S Carolina, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29425 USA

来源：

JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2013年 / 27卷 / 03期

关键词：

INADEQUATE GLYCEMIC CONTROL; DOUBLE-BLIND; BODY-WEIGHT; ADD-ON; DAPAGLIFLOZIN; MELLITUS; CANAGLIFLOZIN; METFORMIN; INSULIN; HYPERGLYCEMIA;

D O I：

10.1016/j.jdiacomp.2012.12.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Type 2 diabetes mellitus (T2DM) significantly increases morbidity and mortality from cardiovascular disease (CVD). Treatments for patients with T2DM have the potential to reduce cardiovascular (CV) risk. This review focuses on the potential of a new class of antidiabetic agents, the sodium glucose cotransporter 2 (SGLT2) inhibitors, to reduce CV rsk in patients with T2DM through reductions in hyperglycemia, blood pressure (BP), and body weight. The results of clinical trials of SGLT2 inhibitors are summarized and discussed. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：280 / 286

页数：7

共 72 条

[11] Fate of the beta-cell in the pathophysiology of type 2 diabetes [J].

Campbell, R. Keith .

JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2009, 49 :S10-S15

[12]

Cefalu W. T., 2012, DIABETES S1A, V61, P10

[13] American Diabetes Association-European Association for the Study of Diabetes Position Statement: Due Diligence Was Conducted [J].

Cefalu, William T. .

DIABETES CARE, 2012, 35 (06) :1201-1203

[14] Evolving Treatment Strategies for the Management of Type 2 Diabetes [J].

Cefalu, William T. .

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2012, 343 (01) :21-26

[15]

Cefalu William T, 2009, Cleve Clin J Med, V76 Suppl 5, pS39, DOI 10.3949/ccjm.76.s5.06

[16] Solute carrier family 2, member 9 and uric acid homeostasis [J].

Cheeseman, Chris .

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2009, 18 (05) :428-432

[17] Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach [J].

Cornell, S. .

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (03) :254-259

[18] National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants [J].

Danaei, Goodarz ;

Finucane, Mariel M. ;

Lu, Yuan ;

Singh, Gitanjali M. ;

Cowan, Melanie J. ;

Paciorek, Christopher J. ;

Lin, John K. ;

Farzadfar, Farshad ;

Khang, Young-Ho ;

Stevens, Gretchen A. ;

Rao, Mayuree ;

Ali, Mohammed K. ;

Riley, Leanne M. ;

Robinson, Carolyn A. ;

Ezzati, Majid .

LANCET, 2011, 378 (9785) :31-40

[19] The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia [J].

DeFronzo, R. A. ;

Davidson, J. A. ;

Del Prato, S. .

DIABETES OBESITY & METABOLISM, 2012, 14 (01) :5-14

[20] Overview of Newer Agents: Where Treatment Is Going [J].

DeFronzo, Ralph A. .

AMERICAN JOURNAL OF MEDICINE, 2010, 123 :S38-S48

← 1 2 3 4 5 6 7 8 →